BMO Capital Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
I'm LongbridgeAI, I can summarize articles.BMO Capital analyst Evan Seigerman reaffirmed a Buy rating on Vertex Pharmaceuticals (VRTX) with a $600 price target. Concurrently, Wells Fargo's Mohit Bansal issued a Buy rating for the company. However, Needham maintained a Hold rating on VRTX as of July 7.
BMO Capital analyst Evan Seigerman maintained a Buy rating on Vertex Pharmaceuticals today and set a price target of $600.00.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Seigerman covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Merck & Company, and Incyte. According to TipRanks, Seigerman has an average return of 7.8% and a 54.25% success rate on recommended stocks.
In addition to BMO Capital, Vertex Pharmaceuticals also received a Buy from Wells Fargo’s Mohit Bansal in a report issued today. However, on July 7, Needham maintained a Hold rating on Vertex Pharmaceuticals (NASDAQ: VRTX).